Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate

Clinical Cancer Research

Volumn 2, Issue 5, 1996, Pages 865-872

  Shack, Sonsoles ^a   Miller, Alexandra ^b   Liu, Lei ^a,c   Prasanna, Premakala ^a   Thibault, Alain ^a,c   Samid, Dvorit ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; DOXORUBICIN; FATTY ACID; GLUTATHIONE; PHENYLACETIC ACID; SUPEROXIDE DISMUTASE; VERAPAMIL;

ARTICLE; BREAST CARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PRIORITY JOURNAL; RECEPTOR UPREGULATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CATALASE; CELL DIFFERENTIATION; CELL DIVISION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HUMANS; P-GLYCOPROTEIN; PHENYLACETATES; PHENYLBUTYRATES; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0029937059     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Nielsen, D., and Skovsgaard, T. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines. Biochim. Biophys. Acta, 1139: 169-183, 1992.
2. Dalton, W. S Clinical and laboratory approaches to drug resistance. Curr. Opin. Oncol., 3: 1043-1048, 1991.
3. Kruh, G. D., and Goldstein, L. J. Doxorubicin and multidrug resistance. Curr. Opin. Oncol., 5: 1029-1034, 1993.
4. Kane, S. E., Pastan, I., and Gottesman, M. M. Genetic basis of multidrug resistance of tumor cells Bioenergetics and Biomembranes 22: 593-617, 1990.
5. Perez, P R., Hamilton, T. C., and Ozols, R. F. Resistance to alkylating agents and cis-platin: insights from ovarian carcinoma model systems. Pharmacol. Ther , 48: 19-27, 1990.
6. Guilbaud, N. F , Gas, N., Dupont, M. A., and Valette, A. Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J. Cell Physiol., 145: 162-172, 1990.
7. Okabe-Kado, J., Hayashi, M., Honma, Y., Hozumi, M., and Tsuruo, T. Inhibition by erythroid differentiation factor (Activin A) of P-glycoprotein expression in multidrug-resistant human K562 erythroleukemia cells. Cancer Res., 51: 2582-2586, 1991.
8. Mickley, L. A., Bates, S E., Richert, N. D., Currier, S., Tanaka, S., Foss, F., Rosen, N., and Fojo, A. T. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents. J. Biol. Chem., 264: 18031-18040, 1989.
9. Ho, S. B., Van, P. S., Dahiya, R., Neuschwander-Tetri, B A., Basbaum, C., and Kim, Y. S. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance. J. Cell. Physiol., 160: 213-226, 1994.
10. Samid, D , Shack, S., and Sherman, L. T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992.
11. Samid, D., Yen, A., and Prasanna, P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood, 80: 1576-1581, 1992.
12. Samid, D., Shack, S., and Myers, C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest., 91: 2288-2295, 1993.
13. Samid, D., Ram, Z., Hudgins, W. R., Shack, S., Liu, L., Walbridge, S., Oldfield, E. H., and Myers, C. E. Selective growth arrest of malignant gliomas by phenylacetate: resemblance to fetal brain damage in phenylketonuria. Cancer Res., 54: 891-895, 1994.
14. Liu, L., Shack, S., Stetler-Stevenson, W. G., Hudgins, W. R., and Samid, D. Differentiation of cultured human-melanoma cells induced by the aromatic fatty-acids pheny lacetate and phenylbutyrate. J. Invest. Dermatol, 103: 335-340, 1994.
15. Thibault, A., Cooper, M. R., Figg, W. D., Venzon, D. J., Sartor, O., Tompkins, A. C., Weinberger, M. S., Headlee, D. J., Konstantinides, F. N., McCall, N. A., Samid, D., and Myers, C. E. A phase I and pharmacokinetics study of intravenous phenylacetate in patients with cancer. Cancer Res., 54: 1690-1694, 1994.
16. Thibault, A., Samid, D., Cooper, M. R., Figg, W. D., Tompkins, A. C., Patronas, N., Headlee, D. J., Kohler, D. R., Venzon, D. J., and Myers, C. E. Phase 1 study of phenylacetate administered twice daily to patients with cancer. Cancer (Phila.), 75: 2982-2938, 1995.
17. Brusilow, S. W., Danney, M., Waber, L. J., Batshaw, M., Burton, B., Levitsky, L., Roth, K., McKeenthren, C., and Ward, J. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N. Engl. J. Med., 310: 1630-1634, 1984.
18. Brusilow, S. W. Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr. Res., 29: 147-150, 1991.
19. Prasanna, P., Shack, S., Wilson, V. L., and Samid, D. Phenylacetate in chemoprevention: in vitro and in vivo suppression of 5-aza-2′-deoxycytidine-induced carcinogenesis. Clin. Cancer Res., 7: 865-871, 1995.
20. Pineau, T., Hudgins, W. R., Liu, L., Chen, L-C., Sher, T., Gonzales, F. J., and Samid, D. Activation of a peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol., in press, 1996.
21. Berembaum, M. C. Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res., 35: 269-335, 1981.
22. Miller, A. C., and Samid, D. Tumor resistance to oxidative stress: association with ras oncogene expression and reversal by lovastatin, an inhibitor of p21ras isoprenylation. Int. J. Cancer, 60: 249-254, 1994.
23. Hammerling, G. J., Klar, D., Pulm, W., Momburh, F., and Moldenhauer, G. The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. Biochim. Biophys. Acta, 907: 245-259, 1987.
24. Wu, L., Smythe, A. M., Stinson, S. F., Mullendore, L. A., Monks, A.. Scudiero, D. A., Paull, K D., Koutsoukos, A. D., Rubinstein, L. V., Boyd, M. R., and Shoemaker, R. H. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res., 52: 3029-3034, 1992.
25. McKibbin, J., Arcolano, L., Karlsson, K. A., Larson, G., Thunn, J., and Brattain, M. Glycosphingolipids of cultured human colon carcinoma cells and their drug-resistant sublines. Biochim. Biophys. Acta, 958: 235-246, 1988.
26. Ramu, A., Glaubiger, D., and Weintraub, H. Differences in lipid composition of doxorubicin-sensitive and resistant p388 cells. Cancer Treat. Rep., 68: 637-641, 1984.
27. Vrignaud, P., Montaudon, D., Londos-Gagtiardi, D., and Robert, J. Fatty acid composition transport and metabolism in doxorubicin-sensitive and -resistant rat glioblastoma cells. Cancer Res., 46: 3258-3261, 1986.
28. Diomede, L., Bizzi, A., Magistrelli, A., Modest, E. J., Salmona, M., and Noseda, A. Role of cell cholesterol in modulating antineoplastic ether lipid uptake, membrane effects and cytotoxicity. Int. J. Cancer, 46: 341-346, 1990.
29. Guffy, M. M., North, J. A., and Burns, C. P. Effect of cellular fatty acid alterations on adriamycin sensitivity in cultured L1210 leukemia cells. Cancer Res., 44: 1863-1866, 1984.
30. Zijlstra, J. G., De Vries, E. G. E., Muskiet, F. A. J., Marini, I. A., Timmer-Bosscha, H., and Mulder, N. H Influence of docosahexaenoic acid in vitro on intracellular Adriamycin concentration in lymphocytes and human Adriamycin-sensitive and -resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines. Int. J. Cancer, 40: 850-856, 1987.
31. Plumb, J. A., Luo, W., and Kerr, D. J. Effect of polyunsaturated fatty acids on the drug sensitivity of human tumor cell lines resistant to either cisplatin or doxorubicin. Br. J. Cancer, 6: 728-733, 1993.
32. Bates, S. E., Mickley, L. A., Chen, Y-N., Richert, N., Rudick, J., Biedler, J. L., and Fojo, A. T. Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation. Mol. Cell. Biol., 9: 4337-4344, 1989.
33. Stockhammer, G., Manley, G. T., Johnson, R., Rosenblum, M. K., Samid, D., and Lieberman, F. S. Inhibition of proliferation and induction of differentiation in medulloblastoma and astrocytoma-derived cell lines with phenylacetate. J. Neurosurg., 83: 672-681, 1995.
34. Lai, G-M., Moscow, J. A., Alvarez, M. G., Fojo, A. T., and Bates, S. E. Contribution of glutathione and giutathione-dependent enzymes in the reversal of Adriamycin resistance in colon carcinoma cell lines. Int. J. Cancer, 49: 688-695, 1991.
35. Doroshow, J. H Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem. Biophys. Res. Commun., 135: 330-335, 1986.